JP4205762B2 - インターロイキン―1β変換酵素のインヒビター - Google Patents
インターロイキン―1β変換酵素のインヒビター Download PDFInfo
- Publication number
- JP4205762B2 JP4205762B2 JP52309897A JP52309897A JP4205762B2 JP 4205762 B2 JP4205762 B2 JP 4205762B2 JP 52309897 A JP52309897 A JP 52309897A JP 52309897 A JP52309897 A JP 52309897A JP 4205762 B2 JP4205762 B2 JP 4205762B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- substituted
- optionally
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(C(C)=O)N(C(C(C)N*)=O)N(*)CC Chemical compound CCC(C(C)=O)N(C(C(C)N*)=O)N(*)CC 0.000 description 60
- ZAQKZHZDSSNRPU-ZWBSKUQPSA-N CC(C(O)=CCC1)=C1C(NC(CCC(NCCC[C@@H](C(N[C@@H](CC(O)=O)C=O)=O)N)=O)C=O)=O Chemical compound CC(C(O)=CCC1)=C1C(NC(CCC(NCCC[C@@H](C(N[C@@H](CC(O)=O)C=O)=O)N)=O)C=O)=O ZAQKZHZDSSNRPU-ZWBSKUQPSA-N 0.000 description 1
- RIFKADJTWUGDOV-UHFFFAOYSA-N CC(C1CCCCC1)=O Chemical compound CC(C1CCCCC1)=O RIFKADJTWUGDOV-UHFFFAOYSA-N 0.000 description 1
- CXVNUSSDNNJPMD-UWPPNVRMSA-N CC(CC=C1)C(NC(CCc2ccccc2)=O)=C1N(CC(N[C@@H](CC(O)=O)C(c1nc(cc(C2CC2)cc2Cl)c2[o]1)=O)=O)C(C1(CC1)NC(CCc1ccccc1)=O)=O Chemical compound CC(CC=C1)C(NC(CCc2ccccc2)=O)=C1N(CC(N[C@@H](CC(O)=O)C(c1nc(cc(C2CC2)cc2Cl)c2[o]1)=O)=O)C(C1(CC1)NC(CCc1ccccc1)=O)=O CXVNUSSDNNJPMD-UWPPNVRMSA-N 0.000 description 1
- ZUUSSGATRSINFZ-UHFFFAOYSA-N CC(NC(CC(O)=O)C=O)=O Chemical compound CC(NC(CC(O)=O)C=O)=O ZUUSSGATRSINFZ-UHFFFAOYSA-N 0.000 description 1
- PFXMTCBWIHOIOH-GQCTYLIASA-N CCC(/C(/C)=C/C(C=O)N)=O Chemical compound CCC(/C(/C)=C/C(C=O)N)=O PFXMTCBWIHOIOH-GQCTYLIASA-N 0.000 description 1
- PMHWEGZPWILHLX-SPIBDARASA-N CCCC[C@@H](C(N[C@@H](CC(O)=O)C=O)=O)NC(C(CCCO)NC(c1cc(cccc2)c2[nH]1)=O)=O Chemical compound CCCC[C@@H](C(N[C@@H](CC(O)=O)C=O)=O)NC(C(CCCO)NC(c1cc(cccc2)c2[nH]1)=O)=O PMHWEGZPWILHLX-SPIBDARASA-N 0.000 description 1
- AHDRFHNMSDNAJV-CFLDLGCGSA-N CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N(C([C@H](CC3)NC(c(cc4)ccc4O)=O)=O)N2C3=O)=O)OC1=O Chemical compound CCO[C@@H]([C@H](C1)NC([C@H](CCC2)N(C([C@H](CC3)NC(c(cc4)ccc4O)=O)=O)N2C3=O)=O)OC1=O AHDRFHNMSDNAJV-CFLDLGCGSA-N 0.000 description 1
- RRPMBOXCLOBWBX-QHGLUPRGSA-N C[C@@H](C1)C(OCc2ccccc2)OC1=O Chemical compound C[C@@H](C1)C(OCc2ccccc2)OC1=O RRPMBOXCLOBWBX-QHGLUPRGSA-N 0.000 description 1
- XMPTWGNIKYLNIR-BMFZPTHFSA-N C[C@H](C(C(c1ccccc1)=O)=O)NC[C@@H](CCC(N(CCC1)N2[C@@H]1C(O)=O)=O)C2=O Chemical compound C[C@H](C(C(c1ccccc1)=O)=O)NC[C@@H](CCC(N(CCC1)N2[C@@H]1C(O)=O)=O)C2=O XMPTWGNIKYLNIR-BMFZPTHFSA-N 0.000 description 1
- FFEWCDLSIYUKML-UHFFFAOYSA-N C[Es](C)=Cc1ccccc1 Chemical compound C[Es](C)=Cc1ccccc1 FFEWCDLSIYUKML-UHFFFAOYSA-N 0.000 description 1
- DTKIWEDJLKINDS-UHFFFAOYSA-O NCCCC(C(NC(C1)C(OCc2ccccc2)OC1=O)=O)[NH2+]C(C(CCC=O)CNC(c1ccccc1)=O)=O Chemical compound NCCCC(C(NC(C1)C(OCc2ccccc2)OC1=O)=O)[NH2+]C(C(CCC=O)CNC(c1ccccc1)=O)=O DTKIWEDJLKINDS-UHFFFAOYSA-O 0.000 description 1
- GWKNQYBXWIOOIF-UHFFFAOYSA-N NCCCC(C(NC(CC(O)=O)C=O)=O)NC(C(CCCO)NC(c(cc1)ccc1S(=O)=O)=O)=O Chemical compound NCCCC(C(NC(CC(O)=O)C=O)=O)NC(C(CCCO)NC(c(cc1)ccc1S(=O)=O)=O)=O GWKNQYBXWIOOIF-UHFFFAOYSA-N 0.000 description 1
- GHXUKMRSZSZEQK-UHOSZYNNSA-N O=C(CCC[C@@H](C1)COC1=O)[C@H](CCC1)N(C([C@@H](CC2)NC(c3ccccc3)=O)=O)N1C2=O Chemical compound O=C(CCC[C@@H](C1)COC1=O)[C@H](CCC1)N(C([C@@H](CC2)NC(c3ccccc3)=O)=O)N1C2=O GHXUKMRSZSZEQK-UHOSZYNNSA-N 0.000 description 1
- NIDUTYDXNUZDNY-CXBRBUDWSA-N O=C([C@H](CCC1)N(C(N(CC2)NS(c3cc(cccc4)c4cc3)(=O)=O)=O)N1C2=O)N[C@@H](C1)C(OCc2ccccc2)OC1=O Chemical compound O=C([C@H](CCC1)N(C(N(CC2)NS(c3cc(cccc4)c4cc3)(=O)=O)=O)N1C2=O)N[C@@H](C1)C(OCc2ccccc2)OC1=O NIDUTYDXNUZDNY-CXBRBUDWSA-N 0.000 description 1
- PDFKBXGTIAQJOV-JINQPTGOSA-N OC(C[C@@H](C=O)NC(CN(C(CCC=C1)=C1N(C1NC(c2ccccc2)=O)C(c2ccccc2)=O)C1=O)=O)=O Chemical compound OC(C[C@@H](C=O)NC(CN(C(CCC=C1)=C1N(C1NC(c2ccccc2)=O)C(c2ccccc2)=O)C1=O)=O)=O PDFKBXGTIAQJOV-JINQPTGOSA-N 0.000 description 1
- IHZCKIDHIXJQLJ-ZEQRLZLVSA-N OC(C[C@@H](C=O)NC(CN(c(cccc1)c1N(C[C@@H]1NC(c2ccccc2)=O)C(CCc2ccccc2)=O)C1=O)=O)=O Chemical compound OC(C[C@@H](C=O)NC(CN(c(cccc1)c1N(C[C@@H]1NC(c2ccccc2)=O)C(CCc2ccccc2)=O)C1=O)=O)=O IHZCKIDHIXJQLJ-ZEQRLZLVSA-N 0.000 description 1
- XYGLKPQADUSZKE-UXMRNZNESA-N OC(C[C@@H](C=O)NC(CNC(CCC=C1)=C1N(CC(C=O)NC(c1ccccc1)=O)C(Cc1ccccc1)=O)=O)=O Chemical compound OC(C[C@@H](C=O)NC(CNC(CCC=C1)=C1N(CC(C=O)NC(c1ccccc1)=O)C(Cc1ccccc1)=O)=O)=O XYGLKPQADUSZKE-UXMRNZNESA-N 0.000 description 1
- MVLZAZXWUHFUAD-CBCGPPTASA-N OC([C@H](CCCNC(CC1)=O)NCC1NC(c(cc1)cc(CN2CCOCC2)c1O)=O)N[C@@H](CC(O)=O)C=O Chemical compound OC([C@H](CCCNC(CC1)=O)NCC1NC(c(cc1)cc(CN2CCOCC2)c1O)=O)N[C@@H](CC(O)=O)C=O MVLZAZXWUHFUAD-CBCGPPTASA-N 0.000 description 1
- LKORABJRVWVJPB-FQECFTEESA-N OCC(C(CC[C@@H]1NC(c2nccnc2O)=O)CCc(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O Chemical compound OCC(C(CC[C@@H]1NC(c2nccnc2O)=O)CCc(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O LKORABJRVWVJPB-FQECFTEESA-N 0.000 description 1
- BVXXXPBLEAMULX-KXBFYZLASA-N OCC(N(C[C@@H]1NC(c2cc(O)nc3ccccc23)=O)c(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O Chemical compound OCC(N(C[C@@H]1NC(c2cc(O)nc3ccccc23)=O)c(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O BVXXXPBLEAMULX-KXBFYZLASA-N 0.000 description 1
- WFZVRMLQBPIGNY-JXFKEZNVSA-N OCC(N(C[C@@H]1NC(c2ccnc3ccccc23)=O)c(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O Chemical compound OCC(N(C[C@@H]1NC(c2ccnc3ccccc23)=O)c(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)=O WFZVRMLQBPIGNY-JXFKEZNVSA-N 0.000 description 1
- YRVNEQADTLBKTD-MEFJIFBHSA-N OCC(N(C[C@@H]1NC(c2nccnc2)=O)c2ccccc2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)O Chemical compound OCC(N(C[C@@H]1NC(c2nccnc2)=O)c2ccccc2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O)O YRVNEQADTLBKTD-MEFJIFBHSA-N 0.000 description 1
- DQBDANDACTYSQN-WAXYSGSMSA-N OCCC(CC[C@@H]1NC(c2cccc3cccnc23)=O)CCc(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O Chemical compound OCCC(CC[C@@H]1NC(c2cccc3cccnc23)=O)CCc(cccc2)c2N(CC(N[C@@H](CC(O)=O)C=O)=O)C1=O DQBDANDACTYSQN-WAXYSGSMSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/575,641 | 1995-12-20 | ||
US08/575,641 US6008217A (en) | 1995-12-20 | 1995-12-20 | Inhibitors of interleukin-1β converting enzyme |
US08/598,332 | 1996-02-08 | ||
US08/598,332 US5874424A (en) | 1995-12-20 | 1996-02-08 | Inhibitors of interleukin-1β converting enzyme |
US08/712,878 | 1996-09-12 | ||
US08/712,878 US5985863A (en) | 1996-09-12 | 1996-09-12 | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
US3149596P | 1996-11-26 | 1996-11-26 | |
US60/031,495 | 1996-11-26 | ||
US08/761,483 US6204261B1 (en) | 1995-12-20 | 1996-12-06 | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US08/761,483 | 1996-12-06 | ||
PCT/US1996/020843 WO1997022619A2 (en) | 1995-12-20 | 1996-12-20 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002306094A Division JP2003137896A (ja) | 1995-12-20 | 2002-10-21 | インターロイキン−1β変換酵素のインヒビター |
JP2008159803A Division JP2008285493A (ja) | 1995-12-20 | 2008-06-18 | インターロイキン−1β変換酵素のインヒビター |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002507961A JP2002507961A (ja) | 2002-03-12 |
JP4205762B2 true JP4205762B2 (ja) | 2009-01-07 |
Family
ID=27534345
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52309897A Expired - Fee Related JP4205762B2 (ja) | 1995-12-20 | 1996-12-20 | インターロイキン―1β変換酵素のインヒビター |
JP2002306094A Withdrawn JP2003137896A (ja) | 1995-12-20 | 2002-10-21 | インターロイキン−1β変換酵素のインヒビター |
JP2008159803A Withdrawn JP2008285493A (ja) | 1995-12-20 | 2008-06-18 | インターロイキン−1β変換酵素のインヒビター |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002306094A Withdrawn JP2003137896A (ja) | 1995-12-20 | 2002-10-21 | インターロイキン−1β変換酵素のインヒビター |
JP2008159803A Withdrawn JP2008285493A (ja) | 1995-12-20 | 2008-06-18 | インターロイキン−1β変換酵素のインヒビター |
Country Status (24)
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6531467B2 (en) | 1996-09-12 | 2003-03-11 | Idun Pharmaceuticals, Inc. | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6610683B2 (en) | 1996-09-12 | 2003-08-26 | Idun Pharmaceuticals, Inc. | Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
NZ334906A (en) | 1996-10-11 | 2000-09-29 | Basf Ag | A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor |
JP2001502330A (ja) * | 1996-10-11 | 2001-02-20 | ワーナー―ランバート・コンパニー | スルホンアミド置換アスパラギン酸インターロイキン―1β変換酵素阻害剤 |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
DE69736984T2 (de) | 1996-12-06 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des interleukin-1-beta konvertierenden enzyms |
EP1466921A1 (en) * | 1996-12-06 | 2004-10-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1 beta converting enzyme |
FR2766188B1 (fr) * | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
AU2901899A (en) | 1998-03-09 | 1999-09-27 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
DE69939689D1 (de) | 1998-03-19 | 2008-11-20 | Vertex Pharma | Caspase inhibitoren |
FR2777279B1 (fr) * | 1998-04-08 | 2004-08-13 | Hoechst Marion Roussel Inc | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
FR2777888B1 (fr) | 1998-04-27 | 2004-07-16 | Hoechst Marion Roussel Inc | Nouveaux derives de l'acide (3,4,7,8,9,10-hexahydro-6,10- dioxo-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de medicaments |
FR2777889B1 (fr) | 1998-04-27 | 2004-07-09 | Hoechst Marion Roussel Inc | Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs |
US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6544951B2 (en) | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6703500B2 (en) * | 1998-08-19 | 2004-03-09 | Vertex Pharmaceuticals, Incorporated | Method of preparing bicyclic intermediates from piperazic acid or an ester thereof useful in the manufacture of caspase inhibitors |
US6559304B1 (en) * | 1998-08-19 | 2003-05-06 | Vertex Pharmaceuticals Incorporated | Method for synthesizing caspase inhibitors |
US6177565B1 (en) | 1998-08-19 | 2001-01-23 | Vertex Pharmaceuticals Inc. | Process for synthesizing piperazic acid |
US6201118B1 (en) | 1998-08-19 | 2001-03-13 | Vertex Pharmaceuticals Inc. | Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
FR2802927B1 (fr) * | 1999-12-28 | 2002-03-01 | Hoechst Marion Roussel Inc | Nouveaux derives de diazepine carboxamide, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et leur nouvelle utilisation |
US6515173B1 (en) | 2000-01-13 | 2003-02-04 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6790989B2 (en) | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US20010053764A1 (en) * | 2000-05-12 | 2001-12-20 | Sims John E. | Interleukin-1 inhibitors in the treatment of diseases |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
PT1292697E (pt) * | 2000-06-15 | 2009-10-28 | Smithkline Beecham Corp | Método para a preparação de um polipéptido il-18 fisiologicamente activo |
DE10037310A1 (de) * | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
CN100396680C (zh) * | 2000-12-28 | 2008-06-25 | 第一制药株式会社 | 极迟抗原-4抑制剂 |
IL156064A0 (en) * | 2000-12-28 | 2003-12-23 | Daiichi Seiyaku Co | Vla-4 inhibitors |
RS51125B (sr) * | 2001-01-29 | 2010-10-31 | Laboratoires Serono Sa. | Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja |
CA2443600A1 (en) | 2001-04-19 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | Heterocyclyldicarbamides as caspase inhibitors |
MXPA04003215A (es) * | 2001-10-04 | 2005-01-25 | Johnson & Johnson | Derivados de triazapina como agentes neurotroficos. |
US6821993B1 (en) | 2001-10-04 | 2004-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Triazepine derivatives as neurotrophic agents |
US7115654B2 (en) * | 2002-06-05 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Caspase-1 inhibitors and methods for their use |
RU2005102094A (ru) | 2002-06-28 | 2006-02-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы каспазы и их применение |
AU2003297570A1 (en) * | 2002-11-26 | 2004-06-18 | Advanced Biotherapy, Inc. | Treatment of skin diseases |
CN100366612C (zh) | 2002-12-20 | 2008-02-06 | 沃泰克斯药物股份有限公司 | 4-氧代-3-(1-氧代-1h-异喹啉-2-基乙酰氨基)-戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途 |
PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
US7691894B2 (en) | 2003-07-24 | 2010-04-06 | Daiichi Pharmaceutical Co., Ltd. | Cyclohexanecarboxylic acid compound |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
KR20060088543A (ko) * | 2003-09-25 | 2006-08-04 | 디엠아이 바이오사이언스 인코포레이티드 | 앤-아실-엘-아스파틱산을 이용하는 방법 및 제품 |
US20050233974A1 (en) * | 2003-12-01 | 2005-10-20 | John Randle | Treating infectious diseases using ice inhibitors |
CN100441186C (zh) * | 2003-12-03 | 2008-12-10 | 和记黄埔医药企业有限公司 | 伪石蒜碱的医药用途 |
EP1720893B1 (en) | 2004-02-26 | 2014-08-13 | Baylor Research Institute | Compositions and methods for the systemic treatment of arthritis |
CA2557645C (en) * | 2004-02-27 | 2013-09-24 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
DK2399916T3 (en) * | 2004-03-12 | 2015-03-02 | Vertex Pharma | A process and intermediates for the preparation of asparaginacetal-caspase inhibitors |
TW200539883A (en) * | 2004-04-22 | 2005-12-16 | Procter & Gamble | Tri-substituted ureas as cytokine inhibitors |
CA2566362C (en) * | 2004-05-15 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Treating seizures using ice inhibitors |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
JP2008500374A (ja) * | 2004-05-27 | 2008-01-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 自己炎症性疾患の処置のためのiceインヒビター |
GB0515323D0 (en) * | 2005-07-26 | 2005-08-31 | Electrophoretics Ltd | Mass labels |
DE102005048293A1 (de) * | 2005-10-08 | 2007-04-12 | Sanofi-Aventis Deutschland Gmbh | Retardformulierung für Pralnacasan |
EP1826199A1 (en) * | 2006-02-27 | 2007-08-29 | Technische Universität Wien | Modified amino acids |
WO2008034095A2 (en) * | 2006-09-15 | 2008-03-20 | University Of Utah Research Foundation | Protected enantiopure trifluorothreonines and methods of making and using same |
CA2695244A1 (en) | 2007-08-03 | 2009-02-12 | Sanofi-Aventis | Caspase imaging probes |
US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
WO2011094426A1 (en) | 2010-01-29 | 2011-08-04 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Caspase inhibitors |
WO2012061785A2 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice inhibiting compounds and uses thereof |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
EP2848696A1 (en) | 2013-09-13 | 2015-03-18 | Sanofi-Aventis Deutschland GmbH | Caspase-1 imaging probes |
CN105849097A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン |
EP3330256B1 (en) * | 2015-07-07 | 2021-06-16 | Shionogi & Co., Ltd. | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY |
US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2018107060A1 (en) | 2016-12-09 | 2018-06-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
AU2021289665A1 (en) | 2020-06-10 | 2022-12-15 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
WO2022103960A1 (en) * | 2020-11-13 | 2022-05-19 | Inipharm, Inc. | Dichlorophenol hsd17b13 inhibitors and uses thereof |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
WO2023137035A1 (en) | 2022-01-12 | 2023-07-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US5985863A (en) * | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US4276298A (en) | 1978-03-24 | 1981-06-30 | Merck & Co., Inc. | 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors |
US4337346A (en) * | 1978-11-02 | 1982-06-29 | Sumitomo Chemical Company, Limited | α-Hydroxyaldehyde and a process for preparing the same |
US4369183A (en) | 1979-09-06 | 1983-01-18 | Merck & Co., Inc. | 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors |
US4499295A (en) | 1983-05-09 | 1985-02-12 | G. D. Searle & Co. | Protease inhibitors |
US4584397A (en) | 1983-05-09 | 1986-04-22 | G. D. Searle & Co. | Protease inhibitors |
IL72523A (en) * | 1983-08-12 | 1988-06-30 | Takeda Chemical Industries Ltd | 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them |
US4551279A (en) | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
US5055451A (en) | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
US5158936A (en) | 1986-12-22 | 1992-10-27 | Syntex (U.S.A.) Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
NZ223148A (en) | 1987-01-16 | 1989-10-27 | Merrell Dow Pharma | Peptide derivatives having peptidase inhibition activity |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5081228A (en) | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
US5008245A (en) | 1988-10-27 | 1991-04-16 | University Of Kentucky Research Foundation | Novel peptidyl carbamate inhibitors of the enzyme elastase |
KR0183397B1 (ko) | 1989-05-04 | 1999-05-01 | 존 엠. 스피나토 | 단백질 분해 효소 저해제로서 유용한 사카린 유도체들 및 그의 제조방법 |
CA2021660A1 (en) | 1989-07-26 | 1991-01-27 | Philippe Bey | Peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
AU6712790A (en) | 1989-10-05 | 1991-05-16 | Board Of Trustees Of The Leland Stanford Junior University | Catheter device with insertion stop means |
WO1991015577A1 (en) | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
US5416013A (en) | 1990-04-04 | 1995-05-16 | Sterling Winthrop Inc. | Interleukin 1β protease and interleukin 1β protease inhibitors |
AU7891891A (en) | 1990-05-25 | 1991-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolopyridazine compounds |
US5199980A (en) | 1990-09-21 | 1993-04-06 | Multicolor Specialties, Inc. | Polyurethane-based water-in-water multicolor paint and method for making |
IL99527A (en) | 1990-09-28 | 1997-08-14 | Lilly Co Eli | Tripeptide antithrombotic agents |
EP0504938A3 (en) | 1991-03-22 | 1993-04-14 | Suntory Limited | Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient |
EP0519748B1 (en) | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
US6348570B1 (en) | 1991-08-16 | 2002-02-19 | Merck & Co., Inc. | Chromophore containing compounds and their use in determining interleukin-1β convertase activity |
US5278061A (en) | 1991-08-16 | 1994-01-11 | Merck & Co., Inc. | Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme |
EP0533226A3 (en) | 1991-08-16 | 1993-08-18 | Merck & Co. Inc. | Novel chromophore containing compounds |
DE69229252T2 (de) | 1991-08-16 | 1999-12-16 | Merck & Co Inc | DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert |
DK0600880T3 (da) | 1991-08-30 | 2004-04-13 | Vertex Pharma | Interleukin 1-beta-protease og interleukin 1-beta-proteasehæmmere |
GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
WO1993014777A1 (en) | 1992-01-31 | 1993-08-05 | Merck & Co., Inc. | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
DE69320176T2 (de) | 1992-02-21 | 1999-04-08 | Merck & Co Inc | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
WO1993025694A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Inhibitors of ced-3 and related proteins |
WO1993025683A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | A gene which prevents programmed cell death |
WO1993025685A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Cloning and characterization of the cell death genes ced-3 and ced-4 |
WO1994000154A1 (en) | 1992-06-24 | 1994-01-06 | Merck & Co., Inc. | DNA ENCODING PRECURSOR INTERLEUKIN 1β CONVERTING ENZYME |
JP2602181B2 (ja) | 1992-07-31 | 1997-04-23 | ファイザー・インク. | 消炎薬としてのペプチジル4−アミノ−2,2−ジフルオロ−3−オクソ−1,6−ヘキサン二酸誘導体 |
US5374623A (en) | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
CA2109646C (en) | 1992-11-24 | 2000-03-07 | Gaston O. Daumy | Para-nitroanilide peptides |
EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
CA2122227A1 (en) | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
US5462939A (en) | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
US5411985A (en) | 1993-05-17 | 1995-05-02 | Merck & Co., Inc. | Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme |
JPH0789951A (ja) | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
ES2122145T3 (es) | 1993-06-04 | 1998-12-16 | Vertex Pharma | Fosfiniloximetil-cetonas peptidicas como inhibidores de la enzima convertida de la interleuquina-1 beta. |
ES2114654T3 (es) | 1993-06-08 | 1998-06-01 | Vertex Pharma | Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta. |
JPH08511690A (ja) | 1993-06-24 | 1996-12-10 | ザ・ジェネラル・ホスピタル・コーポレーション | プログラムされた細胞死遺伝子及びタンパク質 |
WO1995005192A1 (en) | 1993-08-13 | 1995-02-23 | Merck & Co., Inc. | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
US5486623A (en) | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
US5508262A (en) | 1993-12-15 | 1996-04-16 | University Of South Florida | Interleukin-1 receptor antagonist decreases severity of acute pancreatitis |
DE69532113T2 (de) | 1994-03-31 | 2004-07-29 | Vertex Pharmaceuticals Inc., Cambridge | Pyrimidin-derivate als interleukin inhibitoren |
AU705321B2 (en) | 1994-04-29 | 1999-05-20 | Vertex Pharmaceuticals Incorporated | Halomethyl amides as IL-1beta protease inhibitors |
CH688319A5 (fr) | 1994-06-03 | 1997-07-31 | Marcham Trading & Investment L | Procédé pour la préparation du céfixime trihydraté. |
US5552400A (en) | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5565430A (en) | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
JP2882756B2 (ja) | 1994-10-12 | 1999-04-12 | 昭和高分子株式会社 | 脂肪族ポリエステル組成物からなる延伸中空成形体 |
US5498616A (en) | 1994-11-04 | 1996-03-12 | Cephalon, Inc. | Cysteine protease and serine protease inhibitors |
TW394764B (en) | 1995-02-14 | 2000-06-21 | Mitsubishi Chemcal Corp | Oxygen-containing heterocyclic derivatives |
US6184244B1 (en) * | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
-
1996
- 1996-12-06 US US08/761,483 patent/US6204261B1/en not_active Expired - Lifetime
- 1996-12-18 IN IN2188CA1996 patent/IN182290B/en unknown
- 1996-12-20 AU AU15222/97A patent/AU735075B2/en not_active Ceased
- 1996-12-20 NZ NZ326610A patent/NZ326610A/xx not_active IP Right Cessation
- 1996-12-20 GE GEAP19964412A patent/GEP20022638B/en unknown
- 1996-12-20 EP EP10010860A patent/EP2295442A3/en not_active Withdrawn
- 1996-12-20 EP EP09004786A patent/EP2083014A3/en not_active Withdrawn
- 1996-12-20 KR KR1020047011964A patent/KR100561504B1/ko not_active IP Right Cessation
- 1996-12-20 UA UA98073924A patent/UA66337C2/uk unknown
- 1996-12-20 AP APAP/P/2002/002539A patent/AP0202539A0/en unknown
- 1996-12-20 JP JP52309897A patent/JP4205762B2/ja not_active Expired - Fee Related
- 1996-12-20 TR TR2002/01217T patent/TR200201217T2/xx unknown
- 1996-12-20 SK SK842-98A patent/SK287195B6/sk not_active IP Right Cessation
- 1996-12-20 CN CN96199828A patent/CN1229412A/zh active Pending
- 1996-12-20 CA CA002239904A patent/CA2239904C/en not_active Expired - Fee Related
- 1996-12-20 EP EP96945318A patent/EP0869967A2/en not_active Withdrawn
- 1996-12-20 AP AP2002002540A patent/AP2002002540A0/xx unknown
- 1996-12-20 AP APAP/P/2002/002540A patent/AP0202540A0/en unknown
- 1996-12-20 BR BRPI9612258A patent/BRPI9612258B8/pt unknown
- 1996-12-20 AP APAP/P/2002/002538A patent/AP0202538A0/en unknown
- 1996-12-20 IL IL12485096A patent/IL124850A0/xx unknown
- 1996-12-20 WO PCT/US1996/020843 patent/WO1997022619A2/en active Search and Examination
- 1996-12-20 TR TR2002/01218T patent/TR200201218T2/xx unknown
- 1996-12-20 TR TR2002/01216T patent/TR200201216T2/xx unknown
- 1996-12-20 CZ CZ20030411A patent/CZ300171B6/cs not_active IP Right Cessation
- 1996-12-20 BR BRPI9612258-7A patent/BR9612258B1/pt not_active IP Right Cessation
- 1996-12-20 PL PL96328527A patent/PL190736B1/pl not_active IP Right Cessation
- 1996-12-20 NZ NZ518094A patent/NZ518094A/en not_active IP Right Cessation
- 1996-12-20 CZ CZ0190698A patent/CZ298171B6/cs not_active IP Right Cessation
-
1998
- 1998-06-05 NO NO19982597A patent/NO326882B1/no not_active IP Right Cessation
- 1998-06-11 IL IL124850A patent/IL124850A/en not_active IP Right Cessation
- 1998-06-12 IS IS4771A patent/IS4771A/is unknown
- 1998-06-19 MX MX9805016A patent/MX9805016A/es unknown
- 1998-07-13 BG BG108927A patent/BG108927A/en unknown
- 1998-07-13 BG BG102624A patent/BG64465B1/bg unknown
-
1999
- 1999-09-21 US US09/400,639 patent/US6258948B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 US US09/773,477 patent/US6423840B1/en not_active Expired - Fee Related
-
2002
- 2002-01-28 US US10/058,522 patent/US20030225269A1/en not_active Abandoned
- 2002-10-21 JP JP2002306094A patent/JP2003137896A/ja not_active Withdrawn
-
2004
- 2004-11-29 US US10/999,865 patent/US20050143436A1/en not_active Abandoned
-
2006
- 2006-09-01 HK HK06109752.3A patent/HK1089435A1/xx not_active IP Right Cessation
-
2007
- 2007-01-18 US US11/655,938 patent/US7790713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-18 JP JP2008159803A patent/JP2008285493A/ja not_active Withdrawn
-
2010
- 2010-05-24 US US12/786,221 patent/US8119631B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4205762B2 (ja) | インターロイキン―1β変換酵素のインヒビター | |
US5874424A (en) | Inhibitors of interleukin-1β converting enzyme | |
JP4190029B2 (ja) | インターロイキン−1β変換酵素のインヒビター | |
JP4094066B2 (ja) | インターロイキン−1β変換酵素のインヒビター | |
JP2008291039A (ja) | インターロイキン−1β変換酵素のインヒビター | |
JP2004143182A (ja) | インターロイキン−1β変換酵素のインヒビター | |
JP4499917B2 (ja) | インターロイキン−1β変換酵素のインヒビターとしての1,2−ジアゼパン誘導体 | |
CN102985439A (zh) | Iap bir结构域结合化合物 | |
JPH08506569A (ja) | エンドテリン変換酵素阻害剤 | |
JP2001505883A (ja) | インターロイキン−1β変換酵素のインヒビター | |
US6008217A (en) | Inhibitors of interleukin-1β converting enzyme | |
US20120165319A1 (en) | Inhibitors of interleukin-1 beta converting enzyme | |
RU2249598C2 (ru) | ИНГИБИТОРЫ ФЕРМЕНТА, КОНВЕРТИРУЮЩЕГО ИНТЕРЛЕЙКИН-1-β | |
KR100856767B1 (ko) | 인터류킨-1 베타 전환효소의 억제제 | |
AU756253B2 (en) | Inhibitors of interleukin-1beta converting enzyme | |
AP1280A (en) | Inhibitors of interleukin-1 converting enzyme. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050906 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080905 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080922 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081017 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111024 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121024 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |